02205nas a2200289 4500000000100000008004100001653001400042653001800056653001600074653001100090653002000101653001700121653001500138653001500153653001400168100001800182700000900200700001200209700001200221700001400233245012200247856007500369300001000444490000600454520144100460022001401901 2016 d10aNeoplasms10aMycobacterium10aMCF-7 Cells10aHumans10aHot Temperature10aHep G2 Cells10aHela Cells10aCytotoxins10aApoptosis1 aSubramaniam M1 aIn L1 aKumar A1 aAhmed N1 aNagoor NH00aCytotoxic and apoptotic effects of heat killed Mycobacterium indicus pranii (MIP) on various human cancer cell lines. uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730151/pdf/srep19833.pdf a198330 v63 a

Mycobacterium indicus pranii (MIP) is a non-pathogenic mycobacterium, which has been tested on several cancer types like lung and bladder where tumour regression and complete recovery was observed. In discovering the potential cytotoxic elements, a preliminary test was carried out using four different fractions consisting of live bacteria, culture supernatant, heat killed bacteria and heat killed culture supernatant of MIP against two human cancer cells A549 and CaSki by 3-(4,5-dimethyl thiazol)-2,5-diphenyl tetrazolium bromide (MTT) assay. Apoptosis was investigated in MCF-7 and ORL-115 cancer cells by poly-(ADP-ribose) polymerase (PARP) and DNA fragmentation assays. Among four MIP fractions, only heat killed MIP fraction (HKB) showed significant cytotoxicity in various cancer cells with inhibitory concentration, IC50 in the range 5.6-35.0 μl/(1.0 × 10(6) MIP cells/ml), while cytotoxicity effects were not observed in the remaining fractions. HKB did not show cytotoxic effects on non-cancerous cells contrary to cancerous cells, suggesting its safe usage and ability to differentially recognize between these cells. Evaluation on PARP assay further suggested that cytotoxicity in cancer cells were potentially induced via caspase-mediated apoptosis. The cytotoxic and apoptotic effects of MIP HKB have indicated that this fraction can be a good candidate to further identify effective anti-cancer agents.

 a2045-2322